[CAS NO. 630420-16-5] Asunaprevir (BMS-650032)

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [630420-16-5]

Catalog

SLK-S4935

Brand

Selleck

CAS

630420-16-5

DESCRIPTION [630420-16-5]

Overview

MDL	MFCD27987900
Molecular Weight	748.29
Molecular Formula	C35H46ClN5O9S
SMILES	N(C(=O)[C@H]1N(C([C@@H](NC(OC(C)(C)C)=O)[C@@](C)(C)C)=O)C[C@H](OC=2C3=C(C(OC)=CN2)C=CC(Cl)=C3)C1)[C@@]4(C(NS(=O)(=O)C5CC5)=O)[C@H](C=C)C4

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	1.3364 mL	6.6819 mL	13.3638 mL
5 mM	0.2673 mL	1.3364 mL	2.6728 mL
10 mM	0.1336 mL	0.6682 mL	1.3364 mL
50 mM	0.0267 mL	0.1336 mL	0.2673 mL

Description

Asunaprevir (BMS-650032) is an orally bioavailable inhibitor of the that is necessary for protein processing required for viral replication.

Targets

In vitro

Asunaprevir (ASV) competitively binds to the NS3/4A protease complex, with Ki values of 0.4 and 0.24 nM against recombinant enzymes representing genotypes 1a (H77) and 1b (J4L6S), respectively. Asunaprevir is high selective without any significant activity against the closely related GB virus-B NS3 protease and a panel of human serine or cysteine proteases. In cell culture, ASV inhibits replication of HCV replicons representing genotypes 1 and 4, with 50% effective concentrations (EC50s) ranging from 1 to 4 nM, and has weaker activity against genotypes 2 and 3 (EC50, 67-1162 nM). Selectivity is again demonstrated by the absence of activity (EC50, >12 μM) against a panel of other RNA viruses.

In vivo

Plasma and tissue exposures in vivo in several animal species indicate that ASV displays a hepatotropic disposition (liver-to-plasma ratios ranging from 40- to 359-fold across species). Twenty-four hours postdose, liver exposures across all species tested are ≥110-fold above the inhibitor EC50s observed with HCV genotype-1 replicons.

References

[1] McPhee F, et al. Antimicrob Agents Chemother. 2012, 56(10):5387-96.
[2] Wei-Lun Tsai, et al. Front Microbiol. 2017, 8: 668.

Synonyms

Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-, (1R,2S)-

(1R,2S)-N-[(1,1-Dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenylcyclopropanecarboxamide

Asunaprevir

BMS 650032

Sunvepra

1-[[N-tert-Butoxycarbonyl-L-tert-leucyl-trans-4-[(7-chloro-4-methoxyisoquinolin-1-yl)oxy]-L-prolyl]amino]-N-(cyclopropylsulfonyl)-(1R,2S)-2-vinylcyclopropane-1-carboxamide